Litcius/Paper detail

Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study

Antoine Desîlets, Félix Blanc‐Durand, Sally C. M. Lau, Taiki Hakozaki, Rui Kitadai, Julie Malo, Wiam Belkaïd, Corentin Richard, Meriem Messaoudene, Lena Cvetkovic, Suzanne Kazandjian, Mustapha Tehfé, Marie Florescu, Kevin Jao, Nathalie Daaboul, Scott Owen, Benjamin Shieh, Jason Agulnik, Victor Cohen, Chloé Charbonneau, Nicolas Marcoux, Normand Blais, Natasha B. Leighl, Penelope A. Bradbury, Geoffrey Liu, Frances A. Shepherd, Houda Bahig, Bertrand Routy, Adrian G. Sacher, Arielle Elkrief

2020European Journal of Cancer78 citationsDOI

Topics & Concepts

DurvalumabMedicineHazard ratioPneumonitisInternal medicineCohortProportional hazards modelLung cancerUnivariate analysisStage (stratigraphy)Retrospective cohort studyConfidence intervalOncologyIncidence (geometry)Survival analysisMultivariate analysisCancerLungImmunotherapyPaleontologyPhysicsNivolumabBiologyOpticsCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations